a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Clinical trial NCT04776330 · RECRUITING

Trial details

NCT number: NCT04776330
Sponsor: Chongqing Precision Biotech Co., Ltd
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma Neoplasm, Plasma Cell Multiple Myeloma in Relapse

Start date: 2021-03-07
Primary completion: 2026-12-31
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.